The ABCB10 Knockout NCI-H1703 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population originating from the NCI-H1703 human lung squamous cell carcinoma line, engineered for targeted disruption of the ABCB10 gene. This polyclonal knockout model, produced without single-cell cloning, minimizes clonal selection effects and offers a versatile platform for interrogating the biological functions of the ABCB10 mitochondrial transporter. Such polyclonal pools are particularly useful for studying genes whose loss may result in heterogeneous phenotypes, as they preserve the diversity of edited alleles.
The NCI-H1703 host cell line was established from a primary lung squamous cell carcinoma and serves as an essential in vitro model for lung cancer biology, including investigations of cell proliferation, migration, and drug resistance. These adherent epithelial cells retain hallmark genetic and metabolic characteristics of squamous lung carcinoma, providing a pathophysiologically relevant context for probing mitochondrial functions and cellular stress responses. Their robust growth and amenability to genetic manipulation and downstream assays further enhance their utility in cancer research.
ABCB10 encodes a mitochondrial inner membrane transporter critical for heme biosynthesis and iron homeostasis. It physically associates with mitoferrin-1 (SLC25A37) to import iron into the mitochondrial matrix and interacts with ferrochelatase (FECH) to catalyze iron incorporation into protoporphyrin IX. Upregulated by transcription factors GATA1 and HIF1?? under oxidative stress, ABCB10 activity modulates downstream effectors including mitochondrial iron levels, heme production, and reactive oxygen species (ROS) balance. Disruption of ABCB10 thus disconnects a key node linking mitochondrial iron trafficking, heme synthesis, and redox regulation.
In the context of lung squamous cell carcinoma, dysregulated iron metabolism and elevated oxidative stress are often observed, and ABCB10 may contribute to these oncogenic features. Knocking out ABCB10 in NCI-H1703 cells enables dissection of how mitochondrial heme-iron homeostasis influences tumor cell survival, proliferation, and response to chemotherapeutics. This model can reveal mitochondrial vulnerabilities and support the identification of novel therapeutic strategies targeting the heme biosynthesis and iron handling pathways in lung cancer.
These polyclonal knockout cells are suitable for a wide array of functional assays, including western blotting and RT-qPCR to verify ABCB10 loss, immunofluorescence for subcellular localization studies, and mitochondrial iron staining or heme quantification to assess metabolic impacts. Researchers can also perform ROS detection and apoptosis assays to evaluate oxidative damage, along with cell proliferation and drug sensitivity testing to examine growth dependencies and treatment effects. These applications facilitate mechanistic studies of mitochondrial ABC transporter activity, heme metabolism, oxidative stress, and cancer biology. For additional details, please contact Ascent Research.
